Of course, the KRAS mutant NSCLC sample size of the three clinical studies is small, and there are differences in patient characteristics, and all patients in Checkmate 057 study has a PD-L1 tumour proportion score (TPS) of 1% or greater. This evidence concerns the gene KRAS and neoplasm.